[Biochemical and experimental aspects of the lipid-lowering drugs pharmacology (author's transl)].
The analysis of the mode of action of lipid-lowering drugs requires a better understanding of the lipoprotein and cholesterol metabolism processes. The strides observed during the last years in this field are conditioning the development of pharmacologic and therapeutic researches. Moreover the use of new experimental models contributes to this progress by multiplying the study ways.
D000818:Animals; D001161:Arteriosclerosis / Q000517:prevention & control; D002645:Chickens; D002784:Cholesterol / Q000378:metabolism; D002994:Clofibrate / Q000494:pharmacology; D010856:Columbidae; D004036:Diet, Atherogenic; D004195:Disease Models, Animal; D004285:Dogs; D000882:Haplorhini; D006801:Humans; D006949:Hyperlipidemias / Q000188:drug therapy / Q000209:etiology; D000960:Hypolipidemic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D007408:Intestinal Absorption; D008066:Lipolysis / Q000187:drug effects; D008074:Lipoproteins / Q000378:metabolism; D051379:Mice; D009539:Nicotinic Acids / Q000494:pharmacology; D011817:Rabbits; D051381:Rats; D013552:Swine
D000960:Hypolipidemic Agents; D008074:Lipoproteins; D009539:Nicotinic Acids; D002784:Cholesterol; D002994:Clofibrate
Aspect biochimiques et expérimentaux de la pharmacologie des médicaments hypolipidémiants.